Tenet Healthcare Option Alert: Jan, 2026 $180 Calls at the Bid: 1500 vs 12 OI

Tenet Healthcare Option Alert: Jan, 2026 $180 Calls at the Bid: 1500 @ $7.41 vs 12 OI; Ref=$136.65

Tenet Healthcare (NYSE:THC) 주식

Tenet Healthcare

Tenet Healthcare is a Dallas-based healthcare services organization. It operates a collection of hospitals (about 50 as of July 2024) and over 500 ambulatory surgery centers and other outpatient facilities across the U.S., primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.

Equities

Government

Large Cap

Regulations

Sector ETFs

Politics

Econ #s

Markets

Movers

ETFs

NOVA

PowerShares Exchange Traded Fund Trust WilderHill Clean Energy Portfolio

SEDG

백악관이 모든 연방 보조금과 대출에 대한 일시적인 동결을 명령하면서 3조 달러의 자금이 재검토를 받게 되었고, 이는 의회의 재정 권력에 대한 법적 및 정치적 충돌의 무대를 설정하여 광범위한 산업에 큰 영향을 미칠 수 있다. 이 지침은 월요일에 예산관리국(OMB)에 의해 발행되었고 여러 언론 매체에 의해 수신되었다. 모든 연방 기관은 프로그램이 도널드 트럼프 대통령의 정책 우선사항과 일치하는지 검토되는 동안 지급을 중단해야 한다.

트럼프의 연방 지출 중단으로 $3조가 위기에 봉착, 클린 에너지, 방산, 의료 등 산업이 위협

News

Trading Ideas

BABA

INCY

INTU

Citigourp Global Markets 2% Protected Notes Linked To The Djia

ULTA

지난 주 가장 성적이 저조했던 대형주들입니다. 당신의 포트폴리오에 포함되어 있나요?1. 타깃 코퍼레이션(NYSE:TGT)의 주식은 회사가 3분기 실적을 발표했으나 예상에 미치지 못하고, 애널리스트들이 주가 목표를 하향 조정한 후 17.83% 하락했다.

타깃, 알리바바 및 테무는 지난주 최악의 성과를 보인 10개 대형주 중 일부 (11월 18일 ~ 11월 22일)

ICLR

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 아이콘(NASDAQ:ICLR)의 주식은 예상보다 저조한 실적을 발표한 후 25.95% 급락했다. 여러 애널리스트들도 주가 목표를 하향 조정했다.

제뉴인 파츠 및 탑빌드가 지난주 최악의 성과를 보인 10개 대형주 중 일부 (10월 21일-10월 25일)

Tenet Healthcare Corporation Common Stock

Tenet Healthcare Corp

THC BIOMED INTL LTD ORD by THC BioMed Intl Ltd.

THC Biomed International Ltd

TH International Limited - Ordinary shares

TH International Ltd

THUNDER BRDG CAP PARTNERS IV INC CL A

THUNDER BRDG CAP PARTNERS IV INC UNIT 1 CL A & 1/5 WT EXP

THUNDER BRDG CAP PARTNERS IV INC WT EXP

THC THERAPEUTICS INC by THC Therapeutics, Inc.

THC Therapeutics Inc

Spinnaker ETF Series Cannabis ETF

Across the recent three months, 8 analysts have shared their insights on Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $169.75, with a high estimate of $195.00 and a low estimate of $140.00. This current average has decreased by 12.18% from the previous average price target of $193.29. 
<img src="https://www.benzinga.com/files/images/story/2025/1739469619_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive Tenet Healthcare is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$177.00</td>
<td>$177.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$161.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Tim Rezvan</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$185.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$175.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Benjamin Rossi</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Overweight</td>
<td>$175.00</td>
<td>-</td>
</tr>
<tr>
<td>Jamie Perse</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$140.00</td>
<td>$196.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$150.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>John Ransom</td>
<td>Raymond James</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$195.00</td>
<td>$195.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Tenet Healthcare. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Tenet Healthcare compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Tenet Healthcare's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Tenet Healthcare's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/THC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Tenet Healthcare analyst ratings.</a>
<h2>About Tenet Healthcare</h2>
Tenet Healthcare is a Dallas-based healthcare services organization. It operates a collection of hospitals (about 50 as of July 2024) and over 500 ambulatory surgery centers and other outpatient facilities across the U.S., primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.
<h3>Financial Insights: Tenet Healthcare</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Over the 3 months period, Tenet Healthcare showcased positive performance, achieving a revenue growth rate of 1.11% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 9.22%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Tenet Healthcare's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 12.92% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Tenet Healthcare's ROA stands out, surpassing industry averages. With an impressive ROA of 1.61%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Tenet Healthcare's debt-to-equity ratio is below the industry average. With a ratio of 3.36, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Breaking Down Tenet Healthcare: 8 Analysts Share Their Views

Cantor Fitzgerald analyst Sarah James reiterates Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Overweight and maintains $177 price target.

Price Target

Reiteration

Cantor Fitzgerald Reiterates Overweight on Tenet Healthcare, Maintains $177 Price Target

Barclays analyst Andrew Mok maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Overweight and lowers the price target from $190 to $161.

Barclays Maintains Overweight on Tenet Healthcare, Lowers Price Target to $161

Whales with a lot of money to spend have taken a noticeably bearish stance on Tenet Healthcare.
Looking at options history for Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) we detected 9 trades.
If we consider the specifics of each trade, it is accurate to state that 22% of the investors opened trades with bullish expectations and 44% with bearish.
From the overall spotted trades, 7 are puts, for a total amount of $451,318 and 2, calls, for a total amount of $70,520.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $130.0 to $140.0 for Tenet Healthcare during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Tenet Healthcare's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Tenet Healthcare's substantial trades, within a strike price spectrum from $130.0 to $140.0 over the preceding 30 days.
<h3>Tenet Healthcare Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739375169_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>THC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$12.3</td>
<td>$11.5</td>
<td>$11.82</td>
<td>$140.00</td>
<td>$83.0K</td>
<td align="right">521</td>
<td align="right">70</td>
</tr>
<tr>
<td>THC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$12.7</td>
<td>$11.6</td>
<td>$12.06</td>
<td>$140.00</td>
<td>$82.4K</td>
<td align="right">521</td>
<td align="right">72</td>
</tr>
<tr>
<td>THC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$9.2</td>
<td>$8.4</td>
<td>$8.75</td>
<td>$140.00</td>
<td>$61.0K</td>
<td align="right">426</td>
<td align="right">172</td>
</tr>
<tr>
<td>THC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$9.0</td>
<td>$8.3</td>
<td>$8.57</td>
<td>$135.00</td>
<td>$60.3K</td>
<td align="right">612</td>
<td align="right">171</td>
</tr>
<tr>
<td>THC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$9.4</td>
<td>$8.3</td>
<td>$8.81</td>
<td>$135.00</td>
<td>$60.3K</td>
<td align="right">612</td>
<td align="right">173</td>
</tr>
</tbody>
</table>

<h3>About Tenet Healthcare</h3>
Tenet Healthcare is a Dallas-based healthcare services organization. It operates a collection of hospitals (about 50 as of July 2024) and over 500 ambulatory surgery centers and other outpatient facilities across the U.S., primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.
In light of the recent options history for Tenet Healthcare, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Tenet Healthcare Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 1,157,418, with THC's price down by -6.25%, positioned at $130.16.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 0 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Tenet Healthcare, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Smart Money Is Betting Big In THC Options

WIIM

Tenet Healthcare shares are trading lower after the company reported worse-than-expected Q4 revenue results and issued FY25 net operating revenue guidance below estimates.

2025 Outlook1
Tenet's Outlook for full year 2025 (consolidated and by segment) follows.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">CONSOLIDATED ($ in millions, except per share amounts)</td>
<td colspan="1" rowspan="1">FY 2025 Outlook</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net operating revenues</td>
<td colspan="1" rowspan="1">$20,600 to $21,000</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net income available to Tenet common stockholders</td>
<td colspan="1" rowspan="1">$1,040 to $1,185</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA</td>
<td colspan="1" rowspan="1">$3,975 to $4,175</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA margin</td>
<td colspan="1" rowspan="1">19.3% to 19.9%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Diluted income per common share</td>
<td colspan="1" rowspan="1">$10.95 to $12.47</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted net income</td>
<td colspan="1" rowspan="1">$1,115 to $1,220</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted diluted earnings per share</td>
<td colspan="1" rowspan="1">$11.74 to $12.84</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Equity in earnings of unconsolidated affiliates</td>
<td colspan="1" rowspan="1">$265 to $275</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Depreciation and amortization</td>
<td colspan="1" rowspan="1">$805 to $835</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Interest expense</td>
<td colspan="1" rowspan="1">$795 to $805</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Income tax expense5</td>
<td colspan="1" rowspan="1">$420 to $465</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net income available to NCI</td>
<td colspan="1" rowspan="1">$910 to $960</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Weighted average diluted common shares</td>
<td colspan="1" rowspan="1">~95 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net cash provided by operating activities</td>
<td colspan="1" rowspan="1">$2,500 to $2,850</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted net cash provided by operating activities</td>
<td colspan="1" rowspan="1">$2,600 to $2,900</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Capital expenditures</td>
<td colspan="1" rowspan="1">$700 to $800</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Free cash flow</td>
<td colspan="1" rowspan="1">$1,800 to $2,050</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted free cash flow</td>
<td colspan="1" rowspan="1">$1,900 to $2,100</td>
</tr>
<tr>
<td colspan="1" rowspan="1">NCI cash distributions</td>
<td colspan="1" rowspan="1">$750 to $800</td>
</tr>
</tbody>
</table>
</figure><figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Ambulatory Segment($ in millions)</td>
<td colspan="1" rowspan="1">FY 2025 Outlook</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net operating revenues</td>
<td colspan="1" rowspan="1">$4,850 to $5,000</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA</td>
<td colspan="1" rowspan="1">$1,915 to $1,985</td>
</tr>
<tr>
<td colspan="1" rowspan="1">NCI</td>
<td colspan="1" rowspan="1">$760 to $790</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA less NCI</td>
<td colspan="1" rowspan="1">$1,155 to $1,195</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Changes versus prior year6:</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Same-facility system-wide revenue</td>
<td colspan="1" rowspan="1">Up 3.0% to 6.0%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Hospital Segment ($ in millions)</td>
<td colspan="1" rowspan="1">FY 2025 Outlook</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net operating revenues</td>
<td colspan="1" rowspan="1">$15,750 to $16,000</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA</td>
<td colspan="1" rowspan="1">$2,060 to $2,190</td>
</tr>
<tr>
<td colspan="1" rowspan="1">NCI</td>
<td colspan="1" rowspan="1">$150 to $170</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Changes versus prior year6:</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Inpatient admissions</td>
<td colspan="1" rowspan="1">Up 2.0% to 3.0%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted admissions</td>
<td colspan="1" rowspan="1">Up 2.0% to 3.0%</td>
</tr>
</tbody>
</table>
</figure>

Earnings

Guidance

Health Care

General

Tenet Healthcare Forecasts FY2025 Net Operating Revenues Of $20.6B-$21B Versus Consensus Of $21.28B, With Adjusted EPS Of $11.74-$12.84 Versus Consensus Of $11.53

Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) reported quarterly earnings of $3.44 per share which beat the analyst consensus estimate of $2.97 by 15.82 percent. This is a 28.36 percent increase over earnings of $2.68 per share from the same period last year. The company reported quarterly sales of $5.07 billion which missed the analyst consensus estimate of $5.17 billion by 1.89 percent. This is a 5.71 percent decrease over sales of $5.38 billion the same period last year.

Tenet Healthcare Q4 2024 Adj EPS $3.44 Beats $2.97 Estimate, Sales $5.07B Miss $5.17B Estimate

ACRE

AEIS

AEMD

ALCO

ALKS

AMWL

ASND

ASPN

ATRC

AVXL

AYTU

BIIB

BROS

BXMT

CAMT

CGNX

CHEF

CNCK

CNDT

COOP

CRBG

CRSR

CRWS

CSCO

CTRE

CWST

DENN

EPRT

EQIX

FCPT

FSLY

GAIN

GILT

GLPG

GNRC

GOLD

GROW

HCSG

HOOD

HUBS

IREN

KRNT

MKSI

MLYS

MMLP

NMTC

OPRT

OTLY

PAYC

PEGA

PLMR

PODC

PXLW

PYPD

QDEL

QMCO

QTWO

Earnings Scheduled For February 12, 2025

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/14/25</td>
<td>$75.00</td>
<td>$39.4K</td>
<td>2.1K</td>
<td>8.1K</td>
</tr>
<tr>
<td>AHCO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$10.00</td>
<td>$71.4K</td>
<td>0</td>
<td>4.7K</td>
</tr>
<tr>
<td>THC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$145.00</td>
<td>$105.8K</td>
<td>1.1K</td>
<td>1.0K</td>
</tr>
<tr>
<td>COR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$230.00</td>
<td>$822.5K</td>
<td>495</td>
<td>258</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$35.00</td>
<td>$81.1K</td>
<td>5.1K</td>
<td>217</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$270.00</td>
<td>$140.0K</td>
<td>355</td>
<td>200</td>
</tr>
<tr>
<td>SYK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$390.00</td>
<td>$39.6K</td>
<td>484</td>
<td>151</td>
</tr>
<tr>
<td>MCK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/28/25</td>
<td>$610.00</td>
<td>$53.0K</td>
<td>100</td>
<td>137</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$67.50</td>
<td>$33.6K</td>
<td>1.8K</td>
<td>120</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$860.00</td>
<td>$25.3K</td>
<td>50</td>
<td>112</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we notice a call option trade that happens to be bearish, expiring in 3 day(s) on February 14, 2025. This event was a transfer of 200 contract(s) at a $75.00 strike. The total cost received by the writing party (or parties) was $39.4K, with a price of $197.0 per contract. There were 2192 open contracts at this strike prior to today, and today 8123 contract(s) were bought and sold. 
• Regarding AHCO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHCO#NASDAQ">AHCO</a>), we observe a put option sweep with bearish sentiment. It expires in 220 day(s) on September 19, 2025. Parties traded 476 contract(s) at a $10.00 strike. This particular put needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $71.4K, with a price of $150.0 per contract. There were 0 open contracts at this strike prior to today, and today 4752 contract(s) were bought and sold. 
• For THC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>), we notice a call option sweep that happens to be neutral, expiring in 10 day(s) on February 21, 2025. This event was a transfer of 300 contract(s) at a $145.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $105.8K, with a price of $355.0 per contract. There were 1108 open contracts at this strike prior to today, and today 1040 contract(s) were bought and sold. 
• Regarding COR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>), we observe a call option trade with bearish sentiment. It expires in 339 day(s) on January 16, 2026. Parties traded 250 contract(s) at a $230.00 strike. The total cost received by the writing party (or parties) was $822.5K, with a price of $3290.0 per contract. There were 495 open contracts at this strike prior to today, and today 258 contract(s) were bought and sold. 
• Regarding MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we observe a call option sweep with bullish sentiment. It expires in 339 day(s) on January 16, 2026. Parties traded 100 contract(s) at a $35.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $81.1K, with a price of $812.0 per contract. There were 5109 open contracts at this strike prior to today, and today 217 contract(s) were bought and sold. 
• For AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we notice a put option trade that happens to be bullish, expiring in 129 day(s) on June 20, 2025. This event was a transfer of 200 contract(s) at a $270.00 strike. The total cost received by the writing party (or parties) was $140.0K, with a price of $700.0 per contract. There were 355 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
• For SYK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), we notice a put option sweep that happens to be bearish, expiring in 10 day(s) on February 21, 2025. This event was a transfer of 99 contract(s) at a $390.00 strike. This particular put needed to be split into 23 different trades to become filled. The total cost received by the writing party (or parties) was $39.6K, with a price of $400.0 per contract. There were 484 open contracts at this strike prior to today, and today 151 contract(s) were bought and sold. 
• For MCK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>), we notice a call option sweep that happens to be bullish, expiring in 17 day(s) on February 28, 2025. This event was a transfer of 53 contract(s) at a $610.00 strike. This particular call needed to be split into 16 different trades to become filled. The total cost received by the writing party (or parties) was $53.0K, with a price of $1000.0 per contract. There were 100 open contracts at this strike prior to today, and today 137 contract(s) were bought and sold. 
• Regarding AZN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), we observe a call option sweep with bearish sentiment. It expires in 65 day(s) on April 17, 2025. Parties traded 57 contract(s) at a $67.50 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $33.6K, with a price of $590.0 per contract. There were 1841 open contracts at this strike prior to today, and today 120 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a put option trade that happens to be bearish, expiring in 157 day(s) on July 18, 2025. This event was a transfer of 4 contract(s) at a $860.00 strike. The total cost received by the writing party (or parties) was $25.3K, with a price of $6340.0 per contract. There were 50 open contracts at this strike prior to today, and today 112 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AHCO

AMGN

MRNA

10 Health Care Stocks With Whale Alerts In Today's Session

A nationwide lockout of federal health payment systems, reportedly due to an &#8220;outage&#8221;, has led to widespread criticism of the White House. The lockout affected several organizations and agencies, including state Medicaid programs, federally funded Head Start early education programs, and community health centers.
What Happened: The White House attributed the lockout to an &#8220;outage.&#8221; White House Press Secretary Karoline Leavitt said on X that the administration is &#8220;aware&#8221; of the Medicaid website not functioning.
&#8220;We have confirmed no payments have been affected — they are still being processed and sent,&#8221; said Leavitt.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The White House is aware of the Medicaid website portal outage. We have confirmed no payments have been affected — they are still being processed and sent. We expect the portal will be back online shortly.
&mdash; Karoline Leavitt (@PressSec) <a href="https://twitter.com/PressSec/status/1884329868030271759?ref_src=twsrc%5Etfw">January 28, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The lockout prevented multiple state Medicaid programs from accessing their payment systems. However, operations resumed later the same day, according to a CBS News <a href="https://www.cbsnews.com/news/medicaid-head-start-health-centers-trump-funding-freeze/">report</a>. The incident coincided with President Donald Trump&#8217;s controversial decision to freeze spending across the federal government, leading to heightened criticism from state governments, nonprofits, and lawmakers.
The entities affected were unable to access the Payment Management Services web portal, run by the Department of Health and Human Services (HHS), which processes billions of dollars in payments annually. 
The lockout and the ongoing communication &#8220;pause&#8221; imposed by the Trump administration at HHS led to a flurry of requests for comment from various stakeholders, including the National Association of Medicaid Directors and several lawmakers.
See Also: <a href="https://www.benzinga.com/markets/equities/25/01/43293219/teslas-30k-ev-risks-being-a-nothing-burger-says-gary-black-warns-of-cannibalization-without-a-new-compact-design">Tesla&#8217;s $30K EV Risks Being A &#8216;Nothing Burger,&#8217; Says Gary Black—Warns Of Cannibalization Without A New Compact Design</a>
Why It Matters: The lockout occurred amidst the administration&#8217;s decision to freeze spending across the federal government, a move that has been challenged legally. A federal judge issued a <a href="https://www.benzinga.com/government/regulations/25/01/43292056/judge-blocks-trumps-order-to-freeze-federal-grant-money">temporary stay on the funding freeze</a>, halting the move until further arguments can be heard.
The freeze put<a href="https://www.benzinga.com/25/01/43290381/trumps-federal-spending-freeze-puts-3-trillion-in-limbo-threatens-industries-like-clean-energy-defense-healthcare"> $3 trillion in funding under scrutiny</a>. This directive required all federal agencies to halt disbursements while programs were reviewed for alignment with Trump&#8217;s policy priorities.
The move is expected to hit sectors such as healthcare, education, clean energy and others. Stocks of clean energy companies like Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>). and Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) suffered a downturn. Shares of healthcare-sector firms like Universal Health Services Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) and Tenet Healthcare Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) also were in the red on Tuesday.
Photo Courtesy: Shutterstock.com
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43293715/cathie-wood-dumps-tesla-stock-ahead-of-q4-earnings-ark-invest-loads-up-on-amazon">Cathie Wood Dumps Tesla Stock Ahead Of Q4 Earnings, Ark Invest Loads Up On Amazon</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Trump White House Blames 'Outage' For Medicaid Website Lockout: 'We Have Confirmed No Payments Have Been Affected'

The White House has ordered a temporary freeze on all federal grants and loans, putting $3 trillion in funding under scrutiny and setting the stage for a legal and political showdown over the congressional power of the purse that could heavily impact a <a href="https://www.benzinga.com/markets">wide range of industries.</a>
The directive, issued Monday by the Office of Management and Budget and received by several media outlets, requires all federal agencies to halt disbursements while programs are reviewed for alignment with President Donald Trump's policy priorities.
This includes halting new awards, existing payment and funding for projects until reviewed.
The exact financial impact of the order remains uncertain. Budget experts cited <a href="https://www.washingtonpost.com/business/2025/01/28/trump-spending-freeze-upends-washington-triggering-legal-threats-delays/">by the Washington Post </a>estimate at least tens of billions of dollars are at stake, though the White House directive suggests the total could be significantly higher.
Of the almost $10 trillion spent by the federal government in fiscal 2024, more than $3 trillion was federal financial assistance, Matthew Vaeth, acting director at the OMB, said in the memorandum.
&#8220;Financial assistance should be dedicated to advancing Administration priorities,&#8221; Vaeth said, adding that &#8220;the use of Federal resources to advance Marxist equity, transgenderism, and green new deal social engineering policies is a waste of taxpayer dollars that does not improve the day-to-day lives of those we serve.&#8221;
The White House said that Social Security and Medicare remain untouched. The sweeping pause threatens funding for universities, nonprofits, contractors and private companies that depend on federal assistance.
&#8220;Nothing in this memo should be construed to impact Medicare or Social Security benefits,&#8221; the memo said. 
The immediate focus will be on how agencies handle exemptions. The OMB memo allows federal departments to request case-by-case approvals, which means some funding may still flow, but the process is likely to be slow and politically charged.
Federal agencies have until Feb. 10, 2025, to provide OMB with detailed reports outlining which programs, projects, and activities are affected by the funding pause.
<h3 class="wp-block-heading">Legal, Political Showdown Over Federal Funds </h3>
The move is triggering legal challenges from nonprofits and Democratic-led states.
Within hours of the announcement, lawsuits were filed in federal courts in New York, Illinois and Oregon, arguing that Trump does not have the authority to withhold congressionally approved spending.
Senate Minority Leader Chuck Schumer was among the first to push back, saying Congress-approved investments are legally mandated and asserting the president lacks the authority to override the Impoundment Control Act of 1974, which restricts unilateral executive control over federal funds.
Trump has long argued that the 1974 law is unconstitutional, stating that past presidents had far more discretion over spending before its passage.
<h3 class="wp-block-heading">Which Industries Could Face Trouble?</h3>
Some of the hardest-hit sectors could include clean energy, defense, health care and education, where federal dollars have played a crucial role in driving investment and growth in recent years.
Trump's OMB memo explicitly targeted climate initiatives and green energy programs. Shares of solar and renewable energy companies were among the hardest hit following the federal funding freeze.
The Invesco Solar ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAN#NYSE">TAN</a>) and the Invesco Wilderhill Clean Energy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBW#NYSE">PBW</a>) fell by 2% and 1.3%, respectively, on Tuesday. 
Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) dropped 12%, Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) fell 9.2% and SolarEdge Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) declined 5%. 
Defense contractors such as Lockheed Martin Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>), RTX Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) and Northrop Grumman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>) may also see rising uncertainty. While military spending is unlikely to be cut outright, several defense contractors rely on federal grants for research and development. 
The impact on health care remains unclear. While Medicare is shielded, Medicaid funding — which supports hospitals, managed care providers and pharmaceutical companies — could be at risk.
HCA Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) and Universal Health Services Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) fell by 1% and 1.4%, respectively, while Tenet Healthcare Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) showed resilience Tuesday. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43281252/fed-set-to-signal-no-rush-to-cut-rates-as-wall-street-awaits-policy-clarity">Fed Set To Signal No Rush To Cut Rates As Wall Street Awaits Policy Clarity</a></li>
</ul>
Photo via Shutterstock.

Trump's Federal Spending Freeze Puts $3 Trillion In Limbo, Threatens Industries Like Clean Energy, Defense, Health Care

Tenet Healthcare's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) short percent of float has risen 33.42% since its last report. The company recently reported that it has 3.58 million shares sold short, which is 4.95% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.18 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Tenet Healthcare Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736883015_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Tenet Healthcare has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Tenet Healthcare's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Tenet Healthcare's peer group average for short interest as a percentage of float is 5.24%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(THC) - Analyzing Tenet Healthcare's Short Interest

Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) has outperformed the market over the past 5 years by 16.42% on an annualized basis producing an average annual return of 28.9%. Currently, Tenet Healthcare has a market capitalization of $12.36 billion. 
Buying $1000 In THC: If an investor had bought $1000 of THC stock 5 years ago, it would be worth $3,566.42 today based on a price of $130.00 for THC at the time of writing.
<h3>Tenet Healthcare's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736434812_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Tenet Healthcare 5 Years Ago Would Be Worth Today

16 analysts have shared their evaluations of Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">9</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $184.56, with a high estimate of $217.00 and a low estimate of $140.00. A 0.2% drop is evident in the current average compared to the previous average price target of $184.93. 
<img src="https://www.benzinga.com/files/images/story/2025/1736272841_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Tenet Healthcare by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tim Rezvan</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$185.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$175.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Benjamin Rossi</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Overweight</td>
<td>$175.00</td>
<td>-</td>
</tr>
<tr>
<td>Jamie Perse</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$140.00</td>
<td>$196.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$150.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>John Ransom</td>
<td>Raymond James</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$195.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$190.00</td>
<td>$171.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$205.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$177.00</td>
<td>$168.00</td>
</tr>
<tr>
<td>Jamie Perse</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$196.00</td>
<td>$173.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$183.00</td>
<td>$174.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>A.J. Rice</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$217.00</td>
<td>$197.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$195.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$180.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Matthew Gillmor</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$200.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Tenet Healthcare. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Tenet Healthcare compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Tenet Healthcare's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Tenet Healthcare's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/THC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Tenet Healthcare analyst ratings.</a>
<h2>Discovering Tenet Healthcare: A Closer Look</h2>
Tenet Healthcare is a Dallas-based healthcare services organization. It operates a collection of hospitals (about 50 as of July 2024) and over 500 ambulatory surgery centers and other outpatient facilities across the U.S., primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.
<h3>Tenet Healthcare's Financial Performance</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Tenet Healthcare displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 1.11%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Tenet Healthcare's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 9.22%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 12.92%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Tenet Healthcare's ROA stands out, surpassing industry averages. With an impressive ROA of 1.61%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 3.36, Tenet Healthcare adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Tenet Healthcare: 16 Analysts Share Their Views

Keybanc analyst Tim Rezvan maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Overweight and lowers the price target from $200 to $185.

Keybanc Maintains Overweight on Tenet Healthcare, Lowers Price Target to $185

Truist Securities analyst David Macdonald maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Buy and lowers the price target from $190 to $175.

Truist Securities Maintains Buy on Tenet Healthcare, Lowers Price Target to $175

Tenet Healthcare's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) short percent of float has risen 17.07% since its last report. The company recently reported that it has 2.43 million shares sold short, which is 3.36% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.62 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Tenet Healthcare Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734699614_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Tenet Healthcare has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Tenet Healthcare's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Tenet Healthcare's peer group average for short interest as a percentage of float is 4.82%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Tenet Healthcare's Recent Short Interest

JP Morgan analyst Benjamin Rossi assumes Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Overweight rating and announces Price Target of $175.

Initiation

JP Morgan Assumes Tenet Healthcare at Overweight, Announces Price Target of $175

15 analysts have shared their evaluations of Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">9</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $183.6, along with a high estimate of $217.00 and a low estimate of $140.00. This upward trend is apparent, with the current average reflecting a 1.4% increase from the previous average price target of $181.07.
<img src="https://www.benzinga.com/files/images/story/2024/1734379250_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Tenet Healthcare. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jamie Perse</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$140.00</td>
<td>$196.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$150.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>John Ransom</td>
<td>Raymond James</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$195.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$190.00</td>
<td>$171.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$205.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$177.00</td>
<td>$168.00</td>
</tr>
<tr>
<td>Jamie Perse</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$196.00</td>
<td>$173.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$183.00</td>
<td>$174.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>A.J. Rice</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$217.00</td>
<td>$197.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$195.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$180.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Matthew Gillmor</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$200.00</td>
<td>-</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$168.00</td>
<td>$168.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$168.00</td>
<td>$168.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Tenet Healthcare. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Tenet Healthcare compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Tenet Healthcare's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Tenet Healthcare's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/THC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Tenet Healthcare analyst ratings.</a>
<h2>Delving into Tenet Healthcare's Background</h2>
Tenet Healthcare is a Dallas-based healthcare services organization. It operates a collection of hospitals (about 50 as of July 2024) and over 500 ambulatory surgery centers and other outpatient facilities across the U.S., primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.
<h3>Unraveling the Financial Story of Tenet Healthcare</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Over the 3 months period, Tenet Healthcare showcased positive performance, achieving a revenue growth rate of 1.11% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Tenet Healthcare's net margin is impressive, surpassing industry averages. With a net margin of 9.22%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Tenet Healthcare's ROE excels beyond industry benchmarks, reaching 12.92%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Tenet Healthcare's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.61% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Tenet Healthcare's debt-to-equity ratio is below the industry average at 3.36, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Tenet Healthcare's Future

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>B of A Securities analyst Adam Angelov downgraded the rating for Logitech International S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGI#NASDAQ">LOGI</a>) from Buy to Neutral and lowered the price target from $114 to $92. Logitech shares closed at $84.39 on Friday. See how other analysts view this stock.</li>
<li>Mizuho analyst William Janela downgraded Northern Oil and Gas, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOG#NYSE">NOG</a>) from Outperform to Neutral and maintained the price target of $47. Northern Oil &amp; Gas shares closed at $40.71 on Friday. <a href="https://www.benzinga.com/quote/NOG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Exane BNP Paribas analyst Andrew Grobler downgraded the rating for Robert Half Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RHI#NYSE">RHI</a>) from Outperform to Underperform and announced a $64 price target. Robert Half shares closed at $76.10 on Friday. See how other analysts view this stock.</li>
<li>Goldman Sachs analyst Jamie Perse downgraded Tenet Healthcare Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) from Buy to Neutral and lowered the price target from $196 to $140. Tenet Healthcare shares closed at $136.71 on Friday. <a href="https://www.benzinga.com/quote/THC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Philippe Houchois downgraded Ford Motor Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) from Hold to Underperform and slashed the price target from $12 to $9. Ford shares closed at $10.39 on Friday. <a href="https://www.benzinga.com/quote/F/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying Ford stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="612" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16071010/image-124-1024x612.png" alt="" class="wp-image-693633" style="width:631px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16071010/image-124-1024x612.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16071010/image-124-300x179.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16071010/image-124-768x459.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16071010/image-124.png 1123w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42482639/wall-streets-most-accurate-analysts-give-their-take-on-3-energy-stocks-with-over-6-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Energy Stocks With Over 6% Dividend Yields</a></li>
</ul>

Downgrades

LOGI

This Ford Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday

Press Releases

Tenet Reports Strong Second Quarter 2024 Results; Raises 2024 Financial Outlook

Tenet Healthcare to Sell Five Birmingham Hospitals to Orlando Health

Tenet to Participate in the 2024 Wells Fargo Healthcare Conference

Tenet Completes Sale of Five Hospitals in Birmingham

Tenet to Report its Third Quarter 2024 Results on October 29th

Tenet to Participate in the UBS Global Healthcare Conference

Tenet Reports Strong Third Quarter 2024 Results; Raises 2024 Financial Outlook

Commure to Deploy Ambient AI Platform to Tenet Physician Resources for Enhanced Clinical Workflows

Tenet to Report its Fourth Quarter 2024 Results on February 12th

Tenet Reports Strong Fourth Quarter and FY 2024 Results; Provides 2025 Financial Outlook

Comments

Tenet Healthcare

Unusual Options Activity for

뉴스

파트너 / 기고자

벤징가 글로벌